Terumo (OTCMKTS:TRUMY – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both healthcare companies, but which is the better stock? Analyst RecommendationsThis is a breakdown of recent ratings for Terumo and biote, as provided by MarketBeat. Get Terumo alerts:Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terumo 0 1 0 1 3.00 biote 1 1 1 1 2.50biote has a consensus target price of $2.75, indicating a potential upside of 20.88%. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.